{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-051045","form_type":"8-K","ticker":"CSTL","cik":"0001447362","company_name":"CASTLE BIOSCIENCES INC","filed_at":"2026-07-30T20:06:54+00:00","discovered_at":"2026-07-30T20:08:00.255382+00:00","generated_at":"2026-07-30T20:08:32.220973+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Castle Biosciences Q2 revenue $103.5M (+20% YoY); raises FY2026 guidance to $365-375M","bullets":["Q2 revenue $103.5M vs $86.2M YoY; net loss $2.1M (incl. $11.6M stock comp) vs net income $4.5M.","Core test reports (DecisionDx-Melanoma, TissueCypher) up 32% YoY; TissueCypher reports surged 63% to 14,988.","Raises FY2026 revenue guidance to $365-375M from $345-355M; expects positive Adjusted EBITDA in Q3, Q4, and full year.","Adjusted EBITDA $12.4M vs $10.4M; cash $266.8M.","AdvanceAD-Tx test received NYSDOH approval; first patient enrolled in DETECT-AD study."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-051045","json":"https://secwatch.observer/filing/0001628280-26-051045.json","markdown":"https://secwatch.observer/filing/0001628280-26-051045.md","text":"https://secwatch.observer/filing/0001628280-26-051045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447362/000162828026051045/0001628280-26-051045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447362/000162828026051045/cstl-20260730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-30T20:08:32.220973+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}